With obesity in the United States at epidemic levels, the U.S. Food and Drug Administration (FDA) is being pressured to approve a new weight-loss drug with known significant side effects. In late February, 2012, Qnexa, a drug combining phentermine (an appetite suppressant medication) and topiramate (an anti-seizure medication), received recommendation for approval by the FDA’s Endocrinologic and Metabolic Drug Advisory Committee. This approval came despite the documented risks of birth defects and heart problems from taking this drug that caused this committee to vote against the drug’s approval in 2010. The FDA is expected to decide whether or not to approve Qnexa by April 17.
Supporters say that Qnexa would fill a crucial need.
Critics note that the risk of dangerous side effects of Qnexa is too great, especially because the long-term effects of the drug are still largely unknown.
Few references are mentioning that patients on Qnexa would need to take it for the rest of their lives. If they stop, any weight lost would return.
PRO Issue Link #1: FDA Panel Recommends Approval of Diet Drug Qnexa (2/22/12)
PRO Issue Link #2: Diet Drug Qnexa Nears FDA Approval: Who Will Benefit? (2/23/12)
CON Issue Link #1: FDA Advisory Panel Green-Lights Toxic Weight Loss Pill (2/28/12)
Alliance for Natural Health USA
CON Issue Link #2: FDA Should Reject Qnexa, Another Dangerous Diet Pill, Public Citizen Tells Advisory Committee (2/22/12)
You are invited to add your comments and share other related online resources.
For additional issues with related resources, visit the American Holistic Health Association’s Special Updates eReport Archives and note the monthly Featured Issue. The issue may be related to a health issue or a health freedom issue.